BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16937357)

  • 1. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma.
    Sugawara W; Haruta M; Sasaki F; Watanabe N; Tsunematsu Y; Kikuta A; Kaneko Y
    Pediatr Blood Cancer; 2007 Sep; 49(3):240-9. PubMed ID: 16937357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.
    Honda S; Haruta M; Sugawara W; Sasaki F; Ohira M; Matsunaga T; Yamaoka H; Horie H; Ohnuma N; Nakagawara A; Hiyama E; Todo S; Kaneko Y
    Int J Cancer; 2008 Sep; 123(5):1117-25. PubMed ID: 18537155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients.
    Honda S; Miyagi H; Suzuki H; Minato M; Haruta M; Kaneko Y; Hatanaka KC; Hiyama E; Kamijo T; Okada T; Taketomi A
    Pediatr Surg Int; 2013 Nov; 29(11):1147-52. PubMed ID: 23989600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients.
    Karamitrousis EI; Balgkouranidou I; Xenidis N; Amarantidis K; Biziota E; Koukaki T; Trypsianis G; Karayiannakis A; Bolanaki H; Kolios G; Lianidou E; Kakolyris S
    Technol Cancer Res Treat; 2021; 20():1533033820973279. PubMed ID: 33928818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
    Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
    J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker.
    Misawa A; Tanaka S; Yagyu S; Tsuchiya K; Iehara T; Sugimoto T; Hosoi H
    Br J Cancer; 2009 Jan; 100(2):399-404. PubMed ID: 19165202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population.
    Zhang CY; Zhao YX; Xia RH; Han J; Wang BS; Tian Z; Wang LZ; Hu YH; Li J
    PLoS One; 2014; 9(10):e110159. PubMed ID: 25302792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-catenin and K-ras mutations and RASSF1A promoter methylation in Taiwanese colorectal cancer patients.
    Chen SP; Wu CC; Huang SY; Kang JC; Chiu SC; Yang KL; Pang CY
    Genet Test Mol Biomarkers; 2012 Nov; 16(11):1277-81. PubMed ID: 23009572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
    Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
    Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
    Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
    Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors.
    Zhang HY; Rumilla KM; Jin L; Nakamura N; Stilling GA; Ruebel KH; Hobday TJ; Erlichman C; Erickson LA; Lloyd RV
    Endocrine; 2006 Dec; 30(3):299-306. PubMed ID: 17526942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
    Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
    Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor.
    Ohshima J; Haruta M; Fujiwara Y; Watanabe N; Arai Y; Ariga T; Okita H; Koshinaga T; Oue T; Hinotsu S; Nakadate H; Horie H; Fukuzawa M; Kaneko Y
    Pediatr Blood Cancer; 2012 Sep; 59(3):499-505. PubMed ID: 22457227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
    Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma.
    Takagi H; Sasaki S; Suzuki H; Toyota M; Maruyama R; Nojima M; Yamamoto H; Omata M; Tokino T; Imai K; Shinomura Y
    J Gastroenterol; 2008; 43(5):378-89. PubMed ID: 18592156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
    Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
    Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
    Alvarez C; Tapia T; Cornejo V; Fernandez W; Muñoz A; Camus M; Alvarez M; Devoto L; Carvallo P
    Mol Carcinog; 2013 Jun; 52(6):475-87. PubMed ID: 22315090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population.
    Sinha R; Hussain S; Mehrotra R; Kumar RS; Kumar K; Pande P; Doval DC; Basir SF; Bharadwaj M
    PLoS One; 2013; 8(4):e60142. PubMed ID: 23573237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.